Literature DB >> 12508387

Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.

Frederick Wolfe1, Bruce Freundlich, Walter L Straus.   

Abstract

OBJECTIVE: To determine whether the risk for cardiovascular and/or cerebrovascular disease (CCVD) is increased in rheumatoid arthritis (RA) compared to osteoarthritis (OA), a disease not known to be associated with increased CCVD.
METHODS: In July 1999, a survey was administered to a sample of 11,572 patients (9,093 with RA, 2479 with OA) from the practices of 709 US community-based rheumatologists. Patients reported past and current myocardial infarction (MI), stroke (cerebrovascular accident, CVA), and lifetime congestive heart failure (CHF), and also provided demographic and clinical information. To estimate the impact of recall bias, medical records were obtained and reviewed for a 50% random sample of the patients reporting CCVD events, with 95% of CCVD reported events confirmed by record review.
RESULTS: Patients with RA and OA differed across all demographic variables. In addition, each variable was significantly associated with MI, CHF, and CVA outcomes. Logistic regression was performed to measure the associations of these outcomes with RA as compared to OA, adjusting for age, sex, education level, smoking, income, hypertension, and body mass index. Compared with OA, patients with RA had the following increased risks: for current MI [odds ratio (OR), 95% confidence interval (95% CI)] 2.14, (1.48, 3.09), lifetime MI 1.28 (1.24, 1.33), CHF 1.43 (1.28, 1.59), current CVA 1.70 (1.29, 2.24), and lifetime CVA 1.005 (0.931, 1.196). The adjusted current and lifetime prevalences of MI were 0.76 and 4.14% for RA versus 0.35 and 3.23% respectively for OA; 0.86 and 3.02% (RA) versus 0.50 and 3.03% (OA) for CVA; and for lifetime CHF, 2.34% (RA) versus 1.64% (OA), respectively.
CONCLUSIONS: RA is associated with an increased risk for CCVD morbidity due to MI, CHF, and probably for CVA, and may be an independent risk factor for these events.

Entities:  

Mesh:

Year:  2003        PMID: 12508387

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  91 in total

Review 1.  Complementary and alternative medicine for rheumatoid arthritis and osteoarthritis: an overview of systematic reviews.

Authors:  Edzard Ernst; Paul Posadzki
Journal:  Curr Pain Headache Rep       Date:  2011-12

2.  Inflammation and hypertension in rheumatoid arthritis.

Authors:  Siriporn Manavathongchai; Aihua Bian; Young Hee Rho; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  J Rheumatol       Date:  2013-09-01       Impact factor: 4.666

3.  [Reducing toxicity of methotrexate with folic acid].

Authors:  P Harten
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 4.  What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Authors:  W G Dixon; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2007-01-24       Impact factor: 19.103

Review 5.  4 years after withdrawal of rofecoxib: where do we stand today?

Authors:  W Jaksch; C Dejaco; M Schirmer
Journal:  Rheumatol Int       Date:  2008-07-29       Impact factor: 2.631

Review 6.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

Review 7.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 8.  Biologics and heart failure in rheumatoid arthritis: are we any wiser?

Authors:  Maria I Danila; Nivedita M Patkar; Jeffrey R Curtis; Kenneth G Saag; Gim Gee Teng
Journal:  Curr Opin Rheumatol       Date:  2008-05       Impact factor: 5.006

9.  Diastolic heart function in RA patients.

Authors:  M Wislowska; B Jaszczyk; M Kochmański; S Sypuła; M Sztechman
Journal:  Rheumatol Int       Date:  2007-10-24       Impact factor: 2.631

Review 10.  Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies.

Authors:  G Malviya; F Conti; M Chianelli; F Scopinaro; R A Dierckx; A Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.